dc.contributor.author | van Wamel, Annemieke | |
dc.contributor.author | Sontum, Per C. | |
dc.contributor.author | Healey, Andrew | |
dc.contributor.author | Kvåle, Svein | |
dc.contributor.author | Bush, Nigel | |
dc.contributor.author | Bamber, Jeffrey | |
dc.contributor.author | Davies, Ruth Catharina de Lange | |
dc.date.accessioned | 2017-10-20T11:04:32Z | |
dc.date.available | 2017-10-20T11:04:32Z | |
dc.date.created | 2016-06-27T10:53:21Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Journal of Controlled Release. 2016, 236 15-21. | nb_NO |
dc.identifier.issn | 0168-3659 | |
dc.identifier.uri | http://hdl.handle.net/11250/2461253 | |
dc.description.abstract | Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12 mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120 days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12 mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60 days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120 days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT + Abraxane group 100% of the animals were alive after 120 days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Elsevier | nb_NO |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.title | Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | acceptedVersion | nb_NO |
dc.source.pagenumber | 15-21 | nb_NO |
dc.source.volume | 236 | nb_NO |
dc.source.journal | Journal of Controlled Release | nb_NO |
dc.identifier.doi | 10.1016/j.jconrel.2016.06.018 | |
dc.identifier.cristin | 1364402 | |
dc.relation.project | Norges forskningsråd: 2228604 | nb_NO |
dc.description.localcode | © 2016. This is the authors’ accepted and refereed manuscript to the article. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | nb_NO |
cristin.unitcode | 194,66,20,0 | |
cristin.unitname | Institutt for fysikk | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |